Treat-to-Target Approach Reduces Incidence of Disease Activity

Although healthcare companies in the systemic lupus erythematosus treatment market have made significant advances regarding drug development, certain side effects of these drugs are anticipated to negatively influence market growth. For instance, immunosuppressive drugs are estimated to reach a value of ~US$ 1.5 billion by 2027, and continue to dominate the systemic lupus erythematosus treatment market throughout the forecast period. However, enduring disease activity with recurring flare ups and accumulating toxicity due to glucocorticoids (GC) and immunosuppressive (IS) medications are some of the side effects associated with SLE drugs.

Since SLE is a heterogeneous disease of varying severity, healthcare companies in the systemic lupus erythematosus treatment landscape are beginning to understand that, developing 'one size fits all' immunosuppressive drugs increases the burden of symptoms in patients. This is why, healthcare companies in the systemic lupus erythematosus treatment market are adopting the 'treat-to-target' approach to develop drugs that effectively manage and minimize the incidence of disease activity. Healthcare providers are implementing patient-tailored therapeutic strategies with the introduction of improved biologic agents.

systemic lupus erythematosus treatment market infographic

Request a sample to get extensive insights into the Systemic Lupus Erythematosus Treatment Market 

Biologics and Belimumab Stabilize Therapeutic Armamentarium for Stakeholders in Supply Chain

With the help of successful randomized controlled trials (RCTs) and approvals from health commissions, healthcare companies in the systemic lupus erythematosus treatment market are capitalizing on improved formulations of biologic agents. Other drugs such as biologics and B-cell modulators are projected to be the second-highest revenue generating source for manufacturers, with a value of ~US$ 785 million by 2027. Due to the increasing availability of belimumab, healthcare companies are gaining credibility, as this antibody is found to be efficacious in minimizing flare ups and disease activity. Thus, belimumab has helped stakeholders in the SLE supply chain to maintain a stable therapeutic armamentarium in the market.

Healthcare companies in the systemic lupus erythematosus treatment market are increasing their focus on novel biologic agents that target B cells, T cells, and cytokines, for improving the quality of life in patients. The market value share of the intravenous mode of delivery is estimated to grow from ~39% currently to ~44% by 2027 in the systemic lupus erythematosus treatment market. This is well justified, as healthcare providers are increasingly diagnosing patients with belimumab through intravenous formulations.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Supportive Treatments Help Companies Broaden Revenue Sources

Apart from advancements in drug delivery, healthcare providers in the systemic lupus erythematosus treatment market are offering supportive treatments, since SLE patients are prone to comorbidities. Thus, healthcare companies can supply hospitals and other healthcare providers with vaccinations to prevent common disease problems such as influenza and streptococcus pneumonia. There is also an increasing need for vaccination against the human papilloma virus (HPV) in adult SLE patients.

Maintaining a steady supply chain of calcium and vitamin D supplements can help healthcare companies in the systemic lupus erythematosus treatment market to broaden and increase their bracket for revenue sources. These supplements are highly recommended for patients who are prescribed glucocorticoids, to avoid the risks of GC-induced osteoporosis. Companies should increase research & development to improve bidirectional control of the risk factors associated with cardiovascular diseases (CVD). Doing this will help them understand the disease-related factors associated with the consumption of statins and antihypertensive drugs by CVD patients.

systemic lupus erythematosus treatment market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on Systemic Lupus Erythematosus Treatment Market

Analysts’ Viewpoint

Analysts of the systemic lupus erythematosus treatment market estimate a promising growth for the market during the forecast period. Healthcare providers should prescribe low-dose aspirin in conjunction with antiphospholipid antibodies (aPL) to reduce cardiovascular events in patients.

However, in many cases, ineffective management of SLE leads to severe drug-induced toxicity and organ deterioration. Thus, healthcare providers are increasing awareness about long-term maintenance therapy with hydroxychloroquine, as this technique has improved the life expectancy of SLE sufferers.

Since belimumab is the only targeted therapy approved by health commissions for the treatment of SLE, healthcare companies should increase their focus on developing new molecular formulations of the antibody.

Systemic Lupus Erythematosus Treatment Market: Key Insights

  • Systemic Lupus Erythematosus (SLE) is a prototypic multisystem autoimmune disorder with a broad spectrum of clinical presentations, encompassing almost all organs and tissues. It can affect the skin, joints, kidneys, brain, and other organs.
  • SLE is more common in women than men, and can occur at any age. However, it appears most often in people between the ages of 15 and 44. The disease affects African Americans and Asians more than people from other races.
  • The global systemic lupus erythematosus treatment market was valued at ~US$ 1.7 Bn in 2018.
  • The global systemic lupus erythematosus treatment market is projected to grow at a CAGR of ~7%, and reach a valuation of ~US$ 3 Bn by the year 2027.

Systemic Lupus Erythematosus Treatment Market: Drivers

  • Increase in number of systemic lupus erythematosus (SLE) patients has resulted in growth of the global systemic lupus erythematosus treatment market. According to The Lupus Foundation of America, approximately 1.5 million people in the U.S. and 5 to 6 million people across the world are affected with various forms of lupus. Systemic lupus erythematosus affects around 70% of all cases of lupus.
  • Numerous pipeline products and recent approvals of drugs to treat systemic lupus erythematosus are expected to drive the systemic lupus erythematosus treatment market during the forecast period.
    • In 2019, Merck & Co., Inc., a global leader in autoimmune disease treatment, announced its two potential candidates, Atacicept and Evobrutinib, which are in phase II of clinical trials, to treat conditions such as systemic lupus erythematosus and other autoimmune disorders.
    • GlaxoSmithKline plc. and AstraZeneca have a long list of pipeline drugs for autoimmune disorders. Both companies have one potential drug molecule, i.e. Belimumab+rituximab and Anifrolumab TULIP, respectively, which are in phase III of clinical trials, to treat the SLE disorder.

Systemic Lupus Erythematosus Treatment Market: Segment Analysis

  • In terms of drug, the immunosuppressive drugs segment is the leading segment in the global systemic lupus erythematosus treatment market. This is due to major manufacturers focusing on the launch of new immunosuppressive drugs.
  • In addition, immunosuppressive drugs for the treatment of systemic lupus erythematosus disease are available at low cost, easily accessible, and highly efficient.
  • The intravenous segment is projected to be a highly attractive segment during the forecast period. Major market players focusing on launching new products in the injection form due to its high onset of action and less drug degradation, which is likely to propel the intravenous segment in the global systemic lupus erythematosus treatment market.
  • Retail pharmacies is a highly preferred distribution channel. Increase in the number of retail pharmacy stores across the globe, availability of new products in retail stores, and availability of most of the drugs, i.e. NSAIDS, antimalarial drugs, corticosteroids as OTC drugs in retail stores, are expected to boost the growth of the retail pharmacies segment in the global systemic lupus erythematosus treatment market.

Systemic Lupus Erythematosus Treatment Market: Geographic Overview

  • In terms of region, the global systemic lupus erythematosus treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions for the easy understanding of the overall systemic lupus erythematosus treatment market.
  • North America dominates the global systemic lupus erythematosus treatment market with the largest share. The market in Asia Pacific is projected to grow at the highest CAGR among all regions, and be the most lucrative regional systemic lupus erythematosus treatment market.

Systemic Lupus Erythematosus Treatment Market: Major Players

  • Leading players analyzed in the report on the global systemic lupus erythematosus treatment market include
    • GlaxoSmithKline plc
    • F. Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • AstraZeneca
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Anthera Pharmaceuticals, Inc.
    • ImmuPharma PLC
    • Aurinia Pharmaceuticals, Inc.
  • Companies in the systemic lupus erythematosus treatment market around the world focus on strategic collaborations and innovative product launches to strengthen their market position.
    • On February 21, 2019, Merck & Co., Inc. acquired Immune Design to increase its new product development activity.
  • Each of these players in the global systemic lupus erythematosus treatment market have been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Systemic Lupus Erythematosus Treatment Market - Segmentation

TMR’s study on the global systemic lupus erythematosus treatment market includes information divided into four segments: drug, mode of delivery, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global systemic lupus erythematosus treatment market are discussed in detail.

Drug

Antimalarial Drugs

Non-steroidal Anti-inflammatory Drugs (NSAIDS)

Corticosteroids

Immunosuppressive Drugs

Others (Biologics, B-cell Modulators, etc.)

Mode of Delivery

Intravenous

Subcutaneous

Oral

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Sales

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

1. Preface

    1.1. Report Scope and Market Segmentation 

    1.2. Research Highlights

2. Assumptions and Research Methodology 

    2.1. Assumptions

    2.2. Research Methodology

3. Executive Summary

    3.1. Global Systemic Lupus Erythematosus Treatment Market Snapshot

4. Market Overview

    4.1. Product Overview

    4.2. Key Industry Events

    4.3. Market Dynamics

        4.3.1. Drivers and Restraints Snapshot Analysis

        4.3.2. Drivers

        4.3.3. Restraints 

        4.3.4. Opportunities 

    4.4. Global Systemic Lupus Erythematosus Treatment Market Revenue Projection

    4.5. Global Systemic Lupus Erythematosus Treatment  Market Outlook

5. Market Outlook

    5.1. Key Mergers & Acquisitions

    5.2. Pipeline Analysis

    5.3. Disease Prevalence & Incidence Rate Globally with Key Countries

6. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Drug

    6.1. Introduction 

    6.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug

    6.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Drug

        6.3.1. Antimalarial Drugs

            6.3.1.1. Chloroquine

            6.3.1.2. Hydrochloroquine

        6.3.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

            6.3.2.1. Ibuprofen

            6.3.2.2. Naproxen

            6.3.2.3. Others

        6.3.3. Corticosteroids

            6.3.3.1. Prednisone

            6.3.3.2. Hydrocortisone

            6.3.3.3. Dexamethasone

            6.3.3.4. Others

        6.3.4. Immunosuppressive Drugs

            6.3.4.1. Azathioprine

            6.3.4.2. Cyclophosphamide

            6.3.4.3. Methotrexate

            6.3.4.4. Others

        6.3.5. Others (Biologics, B-cell Modulators, etc.)

7. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Mode of Delivery

    7.1. Introduction 

    7.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Mode of Delivery

    7.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Mode of Delivery

        7.3.1. Intravenous

        7.3.2. Subcutaneous

        7.3.3. Oral

    7.4. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Mode of Delivery

8. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Distribution Channel

    8.1. Introduction 

    8.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    8.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Sales

    8.4. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Distribution Channel

9. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Region

    9.1. Global Systemic Lupus Erythematosus Treatment Market Scenario, by Country

    9.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Region

    9.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Region

        9.3.1. North America

        9.3.2. Europe

        9.3.3. Asia Pacific

        9.3.4. Latin America

        9.3.5. Middle East & Africa

10. North America Systemic Lupus Erythematosus Treatment Market Analysis

    10.1. Key Findings

    10.2. North America Systemic Lupus Erythematosus Treatment Market Overview

    10.3. North America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country

    10.4. North America Systemic Lupus Erythematosus Treatment Market Forecast, by Country

        10.4.1. U.S.

        10.4.2. Canada

    10.5. North America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug

    10.6. North America Systemic Lupus Erythematosus Treatment Market Forecast, by Drug

        10.6.1. Antimalarial Drugs

            10.6.1.1. Chloroquine

            10.6.1.2. Hydrochloroquine

        10.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

            10.6.2.1. Ibuprofen

            10.6.2.2. Naproxen

            10.6.2.3. Others

        10.6.3. Corticosteroids

            10.6.3.1. Prednisone

            10.6.3.2. Hydrocortisone

            10.6.3.3. Dexamethasone

            10.6.3.4. Others

        10.6.4. Immunosuppressive Drugs

            10.6.4.1. Azathioprine

            10.6.4.2. Cyclophosphamide

            10.6.4.3. Methotrexate

            10.6.4.4. Others

        10.6.5. Others (Biologics, B-cell Modulators, etc.)

    10.7. North America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery

    10.8. North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery

        10.8.1. Intravenous

        10.8.2. Subcutaneous

        10.8.3. Oral

    10.9. North America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    10.10. North America Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel

        10.10.1. Hospital Pharmacies

        10.10.2. Retail Pharmacies

        10.10.3. Online Sales

11. Europe Systemic Lupus Erythematosus Treatment Market Analysis

    11.1. Key Findings

    11.2. Europe Systemic Lupus Erythematosus Treatment Market Overview

    11.3. Europe Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

    11.4. Europe Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region

        11.4.1. Germany

        11.4.2. U.K.

        11.4.3. France

        11.4.4. Spain

        11.4.5. Italy

        11.4.6. Rest of Europe

    11.5. Europe Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug

    11.6. Europe Systemic Lupus Erythematosus Treatment Market Forecast, by Drug

        11.6.1. Antimalarial Drugs

            11.6.1.1. Chloroquine

            11.6.1.2. Hydrochloroquine

        11.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

            11.6.2.1. Ibuprofen

            11.6.2.2. Naproxen

            11.6.2.3. Others

        11.6.3. Corticosteroids

            11.6.3.1. Prednisone

            11.6.3.2. Hydrocortisone

            11.6.3.3. Dexamethasone

            11.6.3.4. Others

        11.6.4. Immunosuppressive Drugs

            11.6.4.1. Azathioprine

            11.6.4.2. Cyclophosphamide

            11.6.4.3. Methotrexate

            11.6.4.4. Others

        11.6.5. Others (Biologics, B-cell Modulators, etc.)

    11.7. Europe Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery

    11.8. Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery

        11.8.1. Intravenous

        11.8.2. Subcutaneous

        11.8.3. Oral

    11.9. Europe Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    11.10. Europe Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel

        11.10.1. Hospital Pharmacies

        11.10.2. Retail Pharmacies

        11.10.3. Online Sales

12. Asia Pacific Systemic Lupus Erythematosus Treatment Market Analysis

    12.1. Key Findings

    12.2. Asia Pacific Systemic Lupus Erythematosus Treatment Market Overview

    12.3. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

    12.4. Asia Pacific Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region

        12.4.1. Japan

        12.4.2. China

        12.4.3. India

        12.4.4. Australia & New Zealand

        12.4.5. Rest of Asia Pacific

    12.5. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug

    12.6. Asia Pacific Systemic Lupus Erythematosus Treatment Market Forecast, by Drug

        12.6.1. Antimalarial Drugs

            12.6.1.1. Chloroquine

            12.6.1.2. Hydrochloroquine

        12.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

            12.6.2.1. Ibuprofen

            12.6.2.2. Naproxen

            12.6.2.3. Others

        12.6.3. Corticosteroids

            12.6.3.1. Prednisone

            12.6.3.2. Hydrocortisone

            12.6.3.3. Dexamethasone

            12.6.3.4. Others

        12.6.4. Immunosuppressive Drugs

            12.6.4.1. Azathioprine

            12.6.4.2. Cyclophosphamide

            12.6.4.3. Methotrexate

            12.6.4.4. Others

        12.6.5. Others (Biologics, B-cell Modulators, etc.)

    12.7. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery

    12.8. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery

        12.8.1. Intravenous

        12.8.2. Subcutaneous

        12.8.3. Oral

    12.9. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    12.10. Asia Pacific Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel

        12.10.1. Hospital Pharmacies

        12.10.2. Retail Pharmacies

        12.10.3. Online Sales

13. Latin America Systemic Lupus Erythematosus Treatment Market Analysis

    13.1. Key Findings

    13.2. Latin America Systemic Lupus Erythematosus Treatment Market Overview

    13.3. Latin America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

    13.4. Latin America Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region

        13.4.1. Brazil

        13.4.2. Mexico

        13.4.3. Rest of Latin America

    13.5. Latin America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug

    13.6. Latin America Systemic Lupus Erythematosus Treatment Market Forecast, by Drug

        13.6.1. Antimalarial Drugs

            13.6.1.1. Chloroquine

            13.6.1.2. Hydrochloroquine

        13.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

            13.6.2.1. Ibuprofen

            13.6.2.2. Naproxen

            13.6.2.3. Others

        13.6.3. Corticosteroids

            13.6.3.1. Prednisone

            13.6.3.2. Hydrocortisone

            13.6.3.3. Dexamethasone

            13.6.3.4. Others

        13.6.4. Immunosuppressive Drugs

            13.6.4.1. Azathioprine

            13.6.4.2. Cyclophosphamide

            13.6.4.3. Methotrexate

            13.6.4.4. Others

        13.6.5. Others (Biologics, B-cell Modulators, etc.)

    13.7. Latin America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery

    13.8. Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery

        13.8.1. Intravenous

        13.8.2. Subcutaneous

        13.8.3. Oral

    13.9. Latin America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    13.10. Latin America Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel

        13.10.1. Hospital Pharmacies

        13.10.2. Retail Pharmacies

        13.10.3. Online Sales

14. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Analysis

    14.1. Key Findings

    14.2. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Overview

    14.3. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

    14.4. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region

        14.4.1. GCC Countries

        14.4.2. South Africa

        14.4.3. Rest of Middle East & Africa

    14.5. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug

    14.6. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Forecast, by Drug

        14.6.1. Antimalarial Drugs

            14.6.1.1. Chloroquine

            14.6.1.2. Hydrochloroquine

        14.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)

            14.6.2.1. Ibuprofen

            14.6.2.2. Naproxen

            14.6.2.3. Others

        14.6.3. Corticosteroids

            14.6.3.1. Prednisone

            14.6.3.2. Hydrocortisone

            14.6.3.3. Dexamethasone

            14.6.3.4. Others

        14.6.4. Immunosuppressive Drugs

            14.6.4.1. Azathioprine

            14.6.4.2. Cyclophosphamide

            14.6.4.3. Methotrexate

            14.6.4.4. Others

        14.6.5. Others (Biologics, B-cell Modulators, etc.)

    14.7. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery

    14.8. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery

        14.8.1. Intravenous

        14.8.2. Subcutaneous

        14.8.3. Oral

    14.9. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

    14.10. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel

        14.10.1. Hospital Pharmacies

        14.10.2. Retail Pharmacies

        14.10.3. Online Sales

15. Competitive Landscape

    15.1. Competition Matrix

    15.2. Company Profile

        15.2.1. GlaxoSmithKline plc 

            15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.1.2. Financial Overview

            15.2.1.3. Product Portfolio

            15.2.1.4. SWOT Analysis

            15.2.1.5. Strategic Overview

        15.2.2. F. Hoffmann-La Roche Ltd. 

            15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.2.2. Financial Overview

            15.2.2.3. Product Portfolio

            15.2.2.4. SWOT Analysis

            15.2.2.5. Strategic Overview

        15.2.3. Pfizer, Inc. 

            15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.3.2. Financial Overview

            15.2.3.3. Product Portfolio

            15.2.3.4. SWOT Analysis

            15.2.3.5. Strategic Overview

        15.2.4. AstraZeneca plc

            15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.4.2. Financial Overview

            15.2.4.3. Product Portfolio

            15.2.4.4. SWOT Analysis

            15.2.4.5. Strategic Overview

        15.2.5. Merck & Co., Inc. 

            15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.5.2. Financial Overview

            15.2.5.3. Product Portfolio

            15.2.5.4. SWOT Analysis

            15.2.5.5. Strategic Overview

        15.2.6. Bristol-Myers Squibb Company 

            15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.6.2. Financial Overview

            15.2.6.3. Product Portfolio

            15.2.6.4. SWOT Analysis

            15.2.6.5. Strategic Overview

        15.2.7. Anthera Pharmaceuticals, Inc. 

            15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.7.2. Financial Overview

            15.2.7.3. Product Portfolio

            15.2.7.4. SWOT Analysis

            15.2.7.5. Strategic Overview

        15.2.8. ImmuPharma PLC 

            15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.8.2. Product Portfolio

            15.2.8.3. SWOT Analysis

            15.2.8.4. Strategic Overview

        15.2.9. Aurinia Pharmaceuticals, Inc. 

            15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.9.2. Product Portfolio

            15.2.9.3. SWOT Analysis

            15.2.9.4. Strategic Overview

List of Tables

Table 01: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027

Table 02: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Antimalarial Drugs, 2017–2027

Table 03: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2017–2027

Table 04: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Corticosteroids, 2017–2027

Table 05: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Immunosuppressive Drugs, 2017–2027

Table 06: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery, 2017–2027

Table 07: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 08: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 09: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 10: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027

Table 11: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Antimalarial Drugs, 2017–2027

Table 12: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2017–2027

Table 13: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Corticosteroids, 2017–2027

Table 14: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Immunosuppressive Drugs, 2017–2027

Table 15: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery, 2017–2027

Table 16: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 17: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 18: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027

Table 19: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Antimalarial Drugs, 2017–2027

Table 20: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2017–2027

Table 21: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Corticosteroids, 2017–2027

Table 22: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Immunosuppressive Drugs, 2017–2027

Table 23: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery, 2017–2027

Table 24: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 25: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 26: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027

Table 27: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Antimalarial Drugs, 2017–2027

Table 28: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2017–2027

Table 29: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Corticosteroids, 2017–2027

Table 30: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Immunosuppressive Drugs, 2017–2027

Table 31: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery, 2017–2027

Table 32: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 33: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 34: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027

Table 35: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Antimalarial Drugs, 2017–2027

Table 36: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2017–2027

Table 37: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Corticosteroids, 2017–2027

Table 38: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Immunosuppressive Drugs, 2017–2027

Table 39: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery, 2017–2027

Table 40: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 41: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 42: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027

Table 43: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Antimalarial Drugs, 2017–2027

Table 44: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2017–2027

Table 45: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Corticosteroids, 2017–2027

Table 46: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Immunosuppressive Drugs, 2017–2027

Table 47: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery, 2017–2027

Table 48: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

List of Figures

Figure 01: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027

Figure 02: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) and Forecast, 2019–2027

Figure 03: Global Systemic Lupus Erythematosus Treatment Market Value Share (%), by Drug, 2018

Figure 04: Global Systemic Lupus Erythematosus Treatment Market Value Share (%), by Mode of Delivery, 2018

Figure 05: Global Systemic Lupus Erythematosus Treatment Market Value Share (%), by Distribution Channel, 2018

Figure 06: Global Systemic Lupus Erythematosus Treatment Market Value Share (%), by Region, 2018

Figure 07: Global Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Drug, 2018 and 2027

Figure 08: Global Systemic Lupus Erythematosus Treatment Market Attractiveness, by Drug, 2019–2027

Figure 09: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antimalarial Drugs, 2017–2027

Figure 10: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2017–2027

Figure 11: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Corticosteroids, 2017–2027

Figure 12: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Immunosuppressive Drugs, 2017–2027

Figure 13: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others (Biologics, B-cell Modulators, etc.), 2017–2027

Figure 14: Global Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery, 2018 and 2027

Figure 15: Global Systemic Lupus Erythematosus Treatment Market Attractiveness, by Mode of Delivery, 2019–2027

Figure 16: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Intravenous, 2017–2027

Figure 17: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Subcutoneous, 2017–2027

Figure 18: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2017–2027

Figure 19: Global Systemic Lupus Erythematosus Treatment Market Value Share, by Distribution Channel, 2018 and 2027

Figure 20: Global Systemic Lupus Erythematosus Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 21: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027

Figure 22: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027

Figure 23: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Sales, 2017–2027

Figure 24: Global Systemic Lupus Erythematosus Treatment Market Value Share, by Region, 2018 and 2027 

Figure 25: Global Systemic Lupus Erythematosus Treatment Market Attractiveness, by Region, 2019–2027

Figure 26: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 27: North America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Country, 2018 and 2027

Figure 28: North America Systemic Lupus Erythematosus Treatment Market Attractiveness, by Country, 2019–2027

Figure 29: North America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Drug, 2018 and 2027

Figure 30: North America Systemic Lupus Erythematosus Treatment Market Attractiveness, by Drug, 2019–2027

Figure 31: North America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery, 2018 and 2027

Figure 32: North America Systemic Lupus Erythematosus Treatment Market Attractiveness, by Mode of Delivery, 2019–2027

Figure 33: North America Systemic Lupus Erythematosus Treatment Market Value Share, by Distribution Channel, 2018 and 2027

Figure 34: North America Systemic Lupus Erythematosus Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 35: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 36: Europe Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 37: Europe Systemic Lupus Erythematosus Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 38: Europe Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Drug, 2018 and 2027

Figure 39: Europe Systemic Lupus Erythematosus Treatment Market Attractiveness, by Drug, 2019–2027

Figure 40: Europe Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery, 2018 and 2027

Figure 41: Europe Systemic Lupus Erythematosus Treatment Market Attractiveness, by Mode of Delivery, 2019–2027

Figure 42: Europe Systemic Lupus Erythematosus Treatment Market Value Share, by Distribution Channel, 2018 and 2027

Figure 43: Europe Systemic Lupus Erythematosus Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 44: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 45: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 46: Asia Pacific Systemic Lupus Erythematosus Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 47: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Drug, 2018 and 2027

Figure 48: Asia Pacific Systemic Lupus Erythematosus Treatment Market Attractiveness, by Drug, 2019–2027

Figure 49: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery, 2018 and 2027

Figure 50: Asia Pacific Systemic Lupus Erythematosus Treatment Market Attractiveness, by Mode of Delivery, 2019–2027

Figure 51: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share, by Distribution Channel, 2018 and 2027

Figure 52: Asia Pacific Systemic Lupus Erythematosus Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 53: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 54: Latin America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 55: Latin America Systemic Lupus Erythematosus Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 56: Latin America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Drug, 2018 and 2027

Figure 57: Latin America Systemic Lupus Erythematosus Treatment Market Attractiveness, by Drug, 2019–2027

Figure 58: Latin America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery, 2018 and 2027

Figure 59: Latin America Systemic Lupus Erythematosus Treatment Market Attractiveness, by Mode of Delivery, 2019–2027

Figure 60: Latin America Systemic Lupus Erythematosus Treatment Market Value Share, by Distribution Channel, 2018 and 2027

Figure 61: Latin America Systemic Lupus Erythematosus Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 62: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 63: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 64: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 65: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Drug, 2018 and 2027

Figure 66: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Attractiveness, by Drug, 2019–2027

Figure 67: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery, 2018 and 2027

Figure 68: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Attractiveness, by Mode of Delivery, 2019–2027

Figure 69: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share, by Distribution Channel, 2018 and 2027

Figure 70: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Systemic Lupus Erythematosus Treatment Market